23 October 2024 Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had.
The National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines for breast cancer, providing a boost to Novartis' Kisqali (ribociclib). 24 October 2024
Alpha-9 Oncology, a Canadian radiopharmaceutical company, has raised $175 million in an oversubscribed series C financing round led by Lightspeed Venture Partners and Ascenta Capital. 24 October 2024
The US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practice (ACIP) voted to expand its recommendation for the use of certain pneumococcal vaccines, including Prevnar 20 (20-valent pneumococcal conjugate vaccine) for all adults aged 50 and older. 24 October 2024
Sino-America clinical-stage biotech Eccogene announced that it will receive a $60 million payment from AstraZeneca, which is being triggered by successfully achieving milestones related to the development of ECC5004/AZD5004 including the first patient dosed in the Phase IIb program. 24 October 2024
Swiss pharma giant Roche this morning reported that, in the first nine months of 2024 group sales increased by 6% at CER (2% in francs) to 45.0 billion francs ($52.0 billion). 23 October 2024
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 23 October 2024
Shares of Swedish drugmaker Camurus fell almost 10% to 588.50 kroner yesterday after it revealed that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the new drug application (NDA) for CAM2029 (octreotide) extended-release injection for the treatment of patients with acromegaly. 23 October 2024
The US Department of Health and Human Services (HHS), through the Office of Assistant Secretary for Planning and Evaluation (ASPE), yesterday released new data showing that nearly 1.5 million people with Medicare Part D saved nearly $1 billion in out-of-pocket prescription drugs costs in the first half of 2024 because of the Biden-Harris Administration’s Inflation Reduction Act. 23 October 2024
UK pharma major AstraZeneca’s Alexion Rare Disease unit has received a positive recommendation for Voydeya (danicopan), from the UK’s National Institute for Health and Care Excellence (NICE). 22 October 2024
UK health technology assessor the National Institute for Health and Care Excellence (NICE) has recommended elafibranor 80mg tablets for the treatment of PBC, the drug’s French developer Ipsen announced today. 22 October 2024
Melbourne, Australia-based Telix Pharmaceuticals has announced the launch of Rhine Pharma, a subsidiary aimed at increasing global access to radiopharmaceuticals for cancer treatment and imaging. 22 October 2024
Berlin, Germany-based Ariceum Therapeutics has presented data at the European Association of Nuclear Medicine 2024 conference on its first-in-class radiopharmaceutical drug, 225Ac-satoreotide. 22 October 2024
Philadelphia, USA-based SERB Pharmaceuticals has announced the acquisition of Aurlumyn (iloprost), the only FDA-approved treatment for severe frostbite in the USA. 22 October 2024
The Institute for Clinical and Economic Review (ICER) has released its final report assessing the effectiveness and pricing of key treatments for transthyretin amyloid cardiomyopathy (ATTR-CM). 22 October 2024
Novo Nordisk today announced the headline results from the SOUL cardiovascular outcomes trial. The double-blinded, randomized trial compared oral semaglutide to placebo as an adjunct to standard of care for the prevention of major adverse cardiovascular events (MACE). 21 October 2024
Sweden-based OncoZenge has announced the intention to partner with UK-based specialty pharma Pharmanovia to secure exclusive rights to commercialize BupiZenge in Europe, the Middle East, and Northern Africa (EMENA). 21 October 2024
Gilead Sciences and Merck & Co have announced new results from a Phase II clinical study evaluating the investigational combination of islatravir, an investigational nucleoside reverse transcriptase translocation inhibitor, and lenacapavir, a first-in-class HIV-1 capsid inhibitor. 21 October 2024
Trade group the Association of the British Pharmaceutical Industry (ABPI) has had its say on UK government plans to overhaul the National Health Service (NHS). 21 October 2024
A Japanese-developed treatment for gout, which was twice rejected by the US medicines regulator, has come under by the non-for-profit consumer advocacy group Public Citizen. 22 June 2018
Conference attendees gathered in the cavernous RAI Amsterdam convention center last week to hear the latest data from a therapy area valued at around $44 billion last year, and expected to reach over $50 billion by 2022. 22 June 2018
When US pharma major Eli Lilly and Anglo-Swedish drugmaker AstraZeneca earlier this month announced that they were discontinuing the global Phase III studies of lanabecestat, an oral beta secretase cleaving enzyme (BACE) inhibitor that was being trialled in Alzheimer’s disease, it was not only a disappointment for the companies, but also for the whole class of drugs. 22 June 2018
Roche today announced that Sophie Kornowski-Bonnet, head of Roche Partnering and member of the enlarged corporate executive committee (CEC) since 2012, has accepted a new opportunity and will be leaving the company effective July 31, 2018. 22 June 2018
The National Institute for Health and Care Excellence (NICE) published a positive final appraisal determination (FAD) on Friday for Ocrevus (ocrelizumab) to treat people living with relapsing-remitting multiple sclerosis (RRMS). 21 June 2018
An Expert View from Lynn Lewis, chief commercial officer of contract research organization Envigo, on why she believes that successful collaboration needs to embrace both proactivity and beginning-with-the-end-in-mind. 21 June 2018
In London, Takeda takeover target Shire jumped more than 2% in morning trading on Thursday, after the rare disease expert revealed US regulators had approved a potentially lucrative label expansion for Cinryze (C1 esterase inhibitor). 21 June 2018
Spending on medicines is growing at the slowest rate in years, but according to a new IQVIA Institute for Human Data Science article, at the pharmacy, commercially insured patients with a deductible have their seen out-of-pocket costs for brand medicines increase 50% since 2014. 21 June 2018
Stolberg-based drugmaker Grünenthal has entered into a collaboration with fellow German groups Lead Discovery Center, Max-Planck Innovation and Max Planck Institute of Experimental Medicine (MPI-EM) to develop novel therapies for the neurological disorder Charcot-Marie-Tooth 1A (CMT1A). 21 June 2018
US biopharma company CASI Pharmaceuticals has announced a strategic and long-term manufacturing agreement with Yiling Wanzhou International Pharmaceutical for the manufacturing of entecavir and cilostazol. 21 June 2018
Anika Therapeutics has revealed that a study of Cingal, which combines cross-linked hyaluronic acid and triamcinolone hexacetonide, in patients with osteoarthritis in the knee, missed its primary endpoint in the active-comparator Phase III trial being conducted to support US registration. 21 June 2018
Following a deal late last year that gave Bayer access to valuable customer data, Chinese e-commerce platform Alibaba has entered into another collaboration with a German pharma major, this time Darmstadt’s Merck,. 20 June 2018
As part of an agreement called the EFPIA Code, European drugmakers will in the next ten days release details of payments to healthcare professionals made in 2017. 20 June 2018
London-based buyout fund CVC Capital Partners is in advanced discussions to acquire a controlling stake worth more than 3 billion euros ($3.5 billion) in Italian drugmaker Recordati, the Financial Times reported this morning, citing three people familiar with the transaction. 20 June 2018
India’s Glenmark Pharmaceuticals has been granted approval by the US Food and Drug Administration to manufacture a generic version of GlaxoSmithKline's Malarone (atovaquone/proguanil hydrochloride) at its facility in North Carolina, USA. 20 June 2018
Jesus Gomez-Navarro, vice president, head of oncology clinical research and development at Takeda Oncology, talks of three elements to the unit’s R&D strategy and three highlights in its pipeline when talking to The Pharma Letter about the most exciting abstracts being presented on the company’s cancer candidates at two major conferences this month. 20 June 2018
French pharma major Sanofi has appointed Jean-Baptiste Chasseloup de Chatillon as executive vice president, chief financial officer (CFO) and member of the executive committee, effective October 1, 2018. 19 June 2018
Swiss pharma giant Roche has entered into a definitive merger agreement for Roche to acquire the outstanding shares of Foundation Medicines common stock not already owned by Roche and its affiliates at a price of $137.00 per share in cash. 19 June 2018
Medivir has decided to continue the discussions with the US Food and Drug Administration to agree on the design of the planned pivotal Phase III clinical study of its lead compound remetinostat for the treatment of early-stage cutaneous T-cell lymphoma (CTCL). 19 June 2018
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
Dewpoint is a biotech company pioneering the application of biomolecular condensate biology – the science studying the organization of biomolecules within membrane-less compartments – towards the development of a new generation of therapeutics to address diseases of high unmet need.